Watson Pharmaceuticals, a specialty pharmaceutical company, has confirmed that its subsidiary, Watson Laboratories filed an abbreviated new drug application, or ANDA, with the FDA seeking approval to market Brimonidine Tartrate and Timolol Maleate ophthalmic solution, 0.2%/0.5%. Watson's Brimonidine Tartrate and Timolol Maleate ophthalmic solution,
Mylan, a generic and specialty pharmaceutical company, has completed the acquisition of Bioniche Pharma Holdings, an injectable pharmaceutical company. Bioniche Pharma is providing Mylan with immediate entry into the North American injectables market and a platform for the commercialization of future biosimilar product offerings.
Acacia Pharma Ltd., of Cambridge, UK, started two development programs: APD421, an intravenous formulation of a currently marketed dopamine D2 antagonist, for the prevention and treatment of nausea and vomiting, and APD515, an optimized oromucosal formulation of another marketed drug, in xerostemia.
HORSHAM, Pa., Sept. 8 Teva Pharmaceutical Industries Ltd. today announced the publication of results from a real-life observational study of the General Practice Research Database, which revealed that asthma patients treated with QVAR, either as initial therapy or with an increase in dose, had a similar or better chance of achieving asthma contro
Pharmaceutical company Watson Pharmaceuticals Inc reported on Tuesday that its subsidiary, Watson Laboratories Inc, has received US approval for its generic equivalent to BayerEURs Yasmin oral contraceptive tablet. The US Food and Drug Administration has approved WatsonEURs Abbreviated New Drug Application for Zarah 3 mg/0.03 mg and the company
Watson Pharmaceuticals, a specialty pharmaceutical company, has announced that its subsidiary, Watson Laboratories, has received approval from the FDA for its abbreviated new drug application for Zarah 3mg/0.03mg, the generic equivalent to Bayer's Yasmin. Watson has begun shipping the product.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the Southern District of New York has denied a motion for summary judgment filed by Sandoz Inc./Momenta Pharmaceuticals, Inc., that the patents at issue are invalid for indefiniteness.
NEW YORK Drugstore operator and pharmacy benefits manager CVS Caremark Corp. spent $2.25 million in the second quarter as it lobbied Congress on matters including Medicare coverage and antitrust issues. The company said it lobbied Congress on what the company described as "anti- legislation" such as disclosure of proprietary information and rest
PITTSBURGH Mylan completed its acquisition of Bioniche Pharma Holdings Ltd. for $550 million in cash, the generic drug company said Tuesday, sooner than it had expected. The deal was announced last month and Mylan says the injectable drug maker will add to its profit in the first year after the closing. It makes analgesics, anesthetics and drugs
MORRISTOWN, N.J., Sept. 7 Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5%. Watson's Brimonidine Tartrate and Timolol Mal
Watson Pharmaceuticals, Inc., today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Zarah 3 mg/0.03 mg, the generic equivalent to Bayer's Yasmin. Watson has begun shipping the product.
Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed, we filed a lawsuit against Novel Laboratories, Inc. because Novel is seeking FDA approval to market a generic version of our MoviPrep product. Norgine, B.V. and Norgine Europe, B.V., which we refer to collectively as Norgine, own U.S. Patent No. 7,169,381.
